Saxagliptin hydrate is a selective and reversible DPP4 inhibitor. It demonstrates greater specificity for DPP4 than for either the DPP8 or DPP9 enzymes. It redu...
Sitagliptin phosphate monohydrate
Sitagliptin phosphate is a potent inhibitor of DPP-IV with IC50 of 19 nM in Caco-2 cell extracts. It is used either alone or in combination with other oral anti...
Alogliptin is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.
Trelagliptin is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D).
Sitagliptin phosphate is a potent inhibitor of DPP4 in Caco-2 cell extracts.
Alogliptin benzoate(SYR 322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.
This active molecular is a selective dipeptidyl peptidase 4 (DPP4) inhibitor under the development of Dong-A. Evogliptin improves insulin resistance and delays ...
Teneligliptin hydrobromide is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor. It competitively inhibited human plasma, rat plasma, and human...
A novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes.
Talabostat mesylate is the orally bioavailable mesylate salt of an amino boronic dipeptide with antineoplastic and hematopoiesis- stimulating activities. By cle...
Sitagliptin(MK 0431) is a potent inhibitor of DPP4 with IC50 of 19 nM in Caco-2 cell extracts.
Glyptins are class of oral anti-hyperglycemic agents that inhibit dipeptidyl peptidase 4 (DPP-4), which can act as a serine exopeptidase. ASide from there use i...
Saxagliptin is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD). It is oral...
Omarigliptin is a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor to be used as treatment for type 2 diabetes.
DBPR108 is an IC50=15 nM DPP IV inhibitor displays a more than 3000-fold selectivity over DPP8 DPP9, FAP and DPP-II. TThe in vivo effects of DBPR108, including ...
Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with...
Teneligliptin is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor. It competitively inhibited human plasma, rat plasma, and human recombinant ...